Skip to main content
SpringerLink
Log in

Immunohistochemical labelling for prostate–specific antigen in breast carcinomas

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Immunohistochemical detection of prostate–specific antigen (PSA) is an aid in determining the prostatic origin of metastatic cells. However, small amounts of PSA have also been found in non–prostatic tissues and tumors, for example in some breast carcinomas, by highly sensitive immunofluorometric methods, but also by immunohistochemistry. Our aim was to evaluate the prevalence and prognostic value of histologically confirmed PSA immunoreactivity in breast carcinoma.

Sections of formalin–fixed, paraffin–embedded samples from 171 breast carcinomas were immunostained for PSA. The staining results were compared with the mitotic activity, tumor size, histological grade, steroid receptors and follow–up data. For analysis the material was divided into subgroups according to the patients' age (pre- and postmenopausal). PSA was found by immunohistochemistry in 54 (32) breast carcinomas. In survival analysis of the whole patient material PSA positivity did not show prognostic value. Among premenopausal patients concomitant estrogen receptor and PSA–negativity proved to be associated with high risk of breast cancer death (RR 6.2), also after adjustment for tumor size, histological grade, and axillary lymph node status. Among postmenopausal patients PSA positivity was associated with progesterone receptor positivity and high differentiation but not with age, nodal status, or mitotic activity. PSA can be detected by immunohistochemistry in a considerable number of breast carcinomas. PSA immunoreactivity alone does not seem to have any value as general prognosticator of breast carcinoma patients. However, concomitant absence of PSA and estrogen receptors was an indicator of unfavourable prognosis among premenopausal patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hara M, Inorre T, Fukuyama T: Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jap J Legal Med 25: 322–324, 1971

    Google Scholar 

  2. Wang MC, Valenzuela LA, Murphy GD, Chu TM: Purification of human prostate specific antigen. Invest Urol 17: 159–163, 1979

    Google Scholar 

  3. Henttu P, Vihko P: Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. Ann Med 26: 157–164, 1994

    Google Scholar 

  4. Watt KWK, Lee PJ, M'Timkulu T, Chan WP, Loor R: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166–3170, 1986

    Google Scholar 

  5. MacDonald RJ, Margolius HS, Erdos EG: Molecular biology of tissue kallikrein. Biochem J 253: 313–321, 1988

    Google Scholar 

  6. Shaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli EE: Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 170: 111–120, 1987

    Google Scholar 

  7. Oesterling JE: Prostate specific antigen; a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923, 1991

    Google Scholar 

  8. Epstein JI: PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 20: 757–770, 1993

    Google Scholar 

  9. Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39: 181–195, 1993

    Google Scholar 

  10. Bostwick DG: Prostate-specific antigen. Current role in diagnostic pathology of prostatic cancer. Am J Clin Pathol 102 (Suppl 1): 31–37,1994

    Google Scholar 

  11. Ploch NR, Brawer MK: How to use prostate-specific antigen. Urology 43: 27–35,1994

    Google Scholar 

  12. Breul J, Pickl U, Hartung: Prostate-specific antigen in urine and saliva. J Urol 149: 302A, 1993

    Google Scholar 

  13. Yu H, Diamandis EP: Prostate-specific antigen in milk of lactating women. Clin Chem 41: 54–58, 1995

    Google Scholar 

  14. Yu H, Diamandis EP: Measurement of serum prostate-specific antigen levels in women and prostatectomized men with an ultrasensitive immunoassay technique. J Urol 153: 1004–1008, 1995

    Google Scholar 

  15. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P: prostatespecific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110, 1995

    Google Scholar 

  16. Kuopio T, Ekfors TO, Nikkanen V, Nevalanen TJ: Acinar cell carcinoma of the pancreas. Report of three cases. APMIS 103: 69–78, 1995

    Google Scholar 

  17. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ: Immunohistochemical labelling for prostate-specific antigen in non-prostatic tissues. Pathol Res Pract 192: 233–237, 1996

    Google Scholar 

  18. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, van Poppel HP, van Damme BJ, Baert LV: Detection of prostate-specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 156: 464–468, 1996

    Google Scholar 

  19. Smith MR, Biggar S, Hussain M: prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 55: 2640–2644, 1995

    Google Scholar 

  20. Djavan B, Keffer JH, Molberg K, Roehrborn CG: Falsepositive serum prostate-specific antigen values in a patient with non-Hodgkin-lymphoma of the kidney. Urol 45: 875–878, 1995

    Google Scholar 

  21. Yu H, Diamandis EP: Ultrasensitive time-resolved immuno-fluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39: 2108–2114, 1993

    Google Scholar 

  22. Howarth DJ, Aronson IB, Diamandis EP: Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 75: 1646–1651, 1997

    Google Scholar 

  23. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, Diamandis EP: Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 72: 728–731, 1995

    Google Scholar 

  24. Scarff RW, Torloni H: Histological typing of breast tumors. International histological classification of tumors No 2, Geneva, WHO, 1968

    Google Scholar 

  25. Fisher ER, Sass R, Fisher B: Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (Protocol No. 4). X. Discriminants for tenth year treatment failure. Cancer 53: 712–723, 1984

    Google Scholar 

  26. Kujari HP, Collan YU, Atkin NB: Use of the mitotic counts for the prognosis and grading of breast cancer. Method evaluation study. Pathol Res Pract 190: 593–599, 1994

    Google Scholar 

  27. McGuire WL: Steroid receptors and breast cancer. Hosp Pract 15: 83–88, 1980

    Google Scholar 

  28. Yu H, Diamandis EP, Sutherland DJA: Immunoreactive prostate-specific antigen levels in female and male breast tu176 KA Alanen et al. mors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75–79, 1994

    Google Scholar 

  29. Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA: Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 4: 871–873, 1996

    Google Scholar 

  30. Levesque MA, Clark GM, Yu H, Diamandis EP: Immuno-fluorometric analysis of p53 protein and prostate-specific antigen in breast tumors and their association with other prognostic indicators. Br J Cancer 72: 720–727, 1995

    Google Scholar 

  31. Zarghami N, Grass L, Sauter ER, Diamandis EP: Prostatespecific antigen in serum during the menstrual cycle. Clin Chem 43: 1862–1867, 1997

    Google Scholar 

  32. Diamandis EP, Yu H, Sutherland DJA: Detection of prostatespecific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 301–310, 1994

    Google Scholar 

  33. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H, Diamandis E: Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 5: 967–970, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Turku and University Central Hospital of Turku, Turku, Finland

    Kalle A. Alanen, Teijo Kuopio, Yrjö U. Collan, Pauliina Kronqvist, Laura Juntti & Timo J. Nevalainen

Authors
  1. Kalle A. Alanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teijo Kuopio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yrjö U. Collan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pauliina Kronqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Juntti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timo J. Nevalainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alanen, K.A., Kuopio, T., Collan, Y.U. et al. Immunohistochemical labelling for prostate–specific antigen in breast carcinomas. Breast Cancer Res Treat 56, 167–174 (1999). https://doi.org/10.1023/A:1006210627219

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006210627219

Search

Navigation